Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Valeant Sees Third Quarter Loss Of $973 Million

By Pharmaceutical Processing | October 31, 2013

(The Associated Press)  Valeant Pharmaceuticals lost $973 million in the third quarter, and lowered the top end of its 2013 earnings forecast as it continues to digest an $8.7 billion acquisition of Bausch + Lomb. The Canadian drugmaker said Thursday it recorded a $645 million impairment charge in the quarter tied to an epilepsy treatment, charges of $305 million against Bausch + Lomb, and $142.5 million to settle some litigation.

Overall, the drugmaker’s loss equated to $2.92 per share. Excluding one-time items, it earned $1.43 per share. Last year, the company earned $7.6 million, or two cents per share. Revenue swelled 74 percent to $1.54 billion, due mainly to the acquisition. Analysts surveyed by FactSet expected, on average, earnings of $1.40 per share on $1.68 billion in revenue.

Valeant now expects 2013 earnings of between $6.11 and $6.16 per share on $5.7 billion to $5.9 billion in revenue. That compares to its forecast in August for earnings of $6 to $6.20 per share on revenue of $5.8 billion to $6.2 billion. The stock was down 3.7 percent, or $4.06, to $105 in in pre-market trading about two hours before the market opened today. Shares have risen more than 82 percent so far this year in regular market trading.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE